Routine clinical VL testing

Study enrollment

Routine clinical VL testing

Study follow-up
 

Predicted phenotypic resistance

Patient N months before enrollment VL (ART used)* VL
(copies/mL)		 Mutations NNRTI NRTI N months after study enrollment VL
(copies/mL)		 N months of last VL test after study enrollment VL (copies/mL)
2 6 535 (1a) 2 680 D67N+
K101H+
V106M+
M184V+
G190A+
F227L		 H: EFV; NVP H: 3TC
S: d4T 		6 982 10 ≤400
22 2 42,187 (1a) 1 280 K103N+
V106M+
M184V		 H: EFV; NVP H: 3TC
S: d4T		 6 64,312 9 ≤400
26 7 ≤400 (1a) 1 370 K103N+
M184V		 H: EFV; NVP H: 3TC
S: d4T		 6 ≤400 9 ≤400
27 Treatment was interrupted for 10 months NA (1a) 178 000 K103N H: EFV; NVP S: 3TC; d4T NA NA 5 ≤400
28 6 191 (1a) 56 500 K103N H: EFV; NVP S: 3TC; d4T 4 ≤400 7 ≤400
29 3 19,653 (1a) 42 800 K103N H: EFV; NVP S: 3TC; d4T 3 ≤400 10 ≤400
33 7 ≤400 (1b) 882 000 Wild type S: EFV; NVP S: 3TC; d4T NA NA 6 ≤400
34 2 20,758 (1b) 1 450 Wild type S: EFV; NVP S: 3TC; d4T NA NA 4 ≤400
37 7 ≤400 (1a) 312 000 Wild type S: EFV; NVP S: 3TC; d4T 3 ≤400 8 ≤400
41 6 ≤400 (1a) 1 060 Not amplifiable --- --- 6 ≤400 9 ≤400
42 4 ≤400 (1a) 557 Not amplifiable --- -- 1 ≤400 8 ≤400
43 4 ≤400 (1a) 66 800 Not amplifiable --- -- 3 ≤400 7 ≤400
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI; VL, virus load (copies/mL); TB, tuberculosis; DRM, drug resistance mutations; Line 1a, Efavirenz (EFV) + Lamivudine (3TC) + Stavudine (d4T); Line 1b, Nevirapine (NVP) + 3TC + d4T; Colors for predicted phenotypic resistance were: White if susceptible (S) or potentially-low (PL); Light gray if low (L) or intermediate (I) and dark gray if highly (H) resistant.
Table 4b: Characteristics of patients with virologic failure at study enrollment and re-suppression at follow-up
Goto home»